Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.13
DVA's Cash-to-Debt is ranked lower than
62% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 0.26 vs. DVA: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
DVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: 3.35
Current: 0.13
0.01
3.35
Equity-to-Asset 0.25
DVA's Equity-to-Asset is ranked lower than
81% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. DVA: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
DVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.24 Max: 0.34
Current: 0.25
0.04
0.34
Interest Coverage 4.57
DVA's Interest Coverage is ranked lower than
68% of the 228 Companies
in the Global Medical Care industry.

( Industry Median: 7.25 vs. DVA: 4.57 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: 5.47
Current: 4.57
2.87
5.47
Piotroski F-Score: 7
Altman Z-Score: 2.03
Beneish M-Score: -2.64
WACC vs ROIC
7.20%
10.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 12.85
DVA's Operating Margin % is ranked higher than
72% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 6.49 vs. DVA: 12.85 )
Ranked among companies with meaningful Operating Margin % only.
DVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 12.85
8.49
17.15
Net Margin % 5.97
DVA's Net Margin % is ranked higher than
63% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 4.00 vs. DVA: 5.97 )
Ranked among companies with meaningful Net Margin % only.
DVA' s Net Margin % Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 7.25
Current: 5.97
1.96
7.25
ROE % 18.42
DVA's ROE % is ranked higher than
79% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 9.23 vs. DVA: 18.42 )
Ranked among companies with meaningful ROE % only.
DVA' s ROE % Range Over the Past 10 Years
Min: 5.37  Med: 19.11 Max: 25.64
Current: 18.42
5.37
25.64
ROA % 4.71
DVA's ROA % is ranked higher than
57% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 3.51 vs. DVA: 4.71 )
Ranked among companies with meaningful ROA % only.
DVA' s ROA % Range Over the Past 10 Years
Min: 1.49  Med: 4.95 Max: 5.69
Current: 4.71
1.49
5.69
ROC (Joel Greenblatt) % 57.96
DVA's ROC (Joel Greenblatt) % is ranked higher than
81% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 15.74 vs. DVA: 57.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 38.04  Med: 56.82 Max: 68.47
Current: 57.96
38.04
68.47
3-Year Revenue Growth Rate 9.50
DVA's 3-Year Revenue Growth Rate is ranked higher than
57% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. DVA: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.8  Med: 12.5 Max: 39.8
Current: 9.5
4.8
39.8
3-Year EBITDA Growth Rate 9.70
DVA's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. DVA: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -0.6  Med: 15 Max: 98.2
Current: 9.7
-0.6
98.2
3-Year EPS without NRI Growth Rate 14.10
DVA's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 132 Companies
in the Global Medical Care industry.

( Industry Median: 8.30 vs. DVA: 14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: 14.1
-29
125.5
GuruFocus has detected 2 Warning Signs with DaVita Inc $DVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DVA Guru Trades in Q1 2016

Andreas Halvorsen 1,744,519 sh (New)
Joel Greenblatt 513,100 sh (+69.62%)
Arnold Van Den Berg 328,908 sh (+22.67%)
Jim Simons 1,091,500 sh (+18.11%)
Mario Gabelli 41,563 sh (+4.00%)
Manning & Napier Advisors, Inc 1,911,305 sh (+1.27%)
Warren Buffett 38,565,570 sh (unchged)
Alan Fournier Sold Out
Paul Tudor Jones Sold Out
Ray Dalio 6,600 sh (-79.34%)
» More
Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
Q3 2016

DVA Guru Trades in Q3 2016

Joel Greenblatt 45,595 sh (New)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Manning & Napier Advisors, Inc 1,354,745 sh (-1.52%)
Arnold Van Den Berg 77,285 sh (-2.54%)
Jim Simons 1,313,500 sh (-4.60%)
Ray Dalio 65,300 sh (-14.05%)
Mario Gabelli 32,613 sh (-19.20%)
» More
Q4 2016

DVA Guru Trades in Q4 2016

Steven Cohen 283,200 sh (New)
Richard Pzena 3,327 sh (New)
Joel Greenblatt 440,617 sh (+866.37%)
Ray Dalio 88,244 sh (+35.14%)
Warren Buffett 38,565,570 sh (unchged)
Arnold Van Den Berg Sold Out
Mario Gabelli 21,663 sh (-33.58%)
Jim Simons 844,500 sh (-35.71%)
Manning & Napier Advisors, Inc 288,580 sh (-78.70%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:NYSE:UHS, OTCPK:RMSYF, OTCPK:BDULF, NYSE:EVHC, NAS:WOOF, NYSE:MD, OTCPK:SKHCF, OTCPK:CAKFY, NYSE:HLS, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:AMN, NYSE:THC, OTCPK:RAFLF, NAS:AMED, NYSE:SEM, NAS:TVTY » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc operates kidney dialysis centers and provides related lab services mainly in dialysis centers and in contracted hospitals across the United States. It also operates other ancillary services and strategic initiatives.

DaVita is the dialysis provider, with its 2,400 clinics based in the U.S. The company treats nearly 200,000 patients with end-stage renal disease. In a 2012 deal valued at nearly $4.4 billion, DaVita merged with HealthCare Partners, one of the physician group managers in the U.S., which now represents approximately 25% of consolidated revenue. HCP coordinates care for nearly 800,000 members with a network of thousands of physicians and specialists in California, Florida, Nevada, New Mexico, and Arizona.

Top Ranked Articles about DaVita Inc

Another Attempt to Trumpet a Misjudgment Reflections on mistakes made in another investment analysis
Arnold Van Den Berg Sells Coca-Cola, DaVita Largest trades by the investor in the second quarter
Arnold Van Den Berg (Trades, Portfolio) is a value investor and considers himself a student of Benjamin Graham. His investment research seeks to determine the appraised value of a company, often referred to as intrinsic value. Read more...
Low P/S Ratios for DaVita, ConAgra Foods Gurus have been snapping up these stocks
According to GuruFocus' All-in-One Screener, the following are companies with market caps above $5 billion that are trading with low P/S ratios. Read more...
Weekly CEO Sells Highlights Insiders sell INC Research Holdings, DaVita HealthCare Partners, TE Connectivity, Ruckus Wireless
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: INC Research Holdings Inc. (NASDAQ:INCR), DaVita HealthCare Partners Inc. (NYSE:DVA), TE Connectivity Ltd. (NYSE:TEL) and Ruckus Wireless Inc. (NYSE:RKUS). Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.52
DVA's PE Ratio is ranked higher than
80% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 27.32 vs. DVA: 15.52 )
Ranked among companies with meaningful PE Ratio only.
DVA' s PE Ratio Range Over the Past 10 Years
Min: 11.6  Med: 18.64 Max: 58.72
Current: 15.52
11.6
58.72
Forward PE Ratio 18.21
DVA's Forward PE Ratio is ranked higher than
61% of the 83 Companies
in the Global Medical Care industry.

( Industry Median: 19.61 vs. DVA: 18.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.52
DVA's PE Ratio without NRI is ranked higher than
80% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 27.32 vs. DVA: 15.52 )
Ranked among companies with meaningful PE Ratio without NRI only.
DVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.57  Med: 18.63 Max: 58.72
Current: 15.52
11.57
58.72
Price-to-Owner-Earnings 10.77
DVA's Price-to-Owner-Earnings is ranked higher than
86% of the 93 Companies
in the Global Medical Care industry.

( Industry Median: 27.69 vs. DVA: 10.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.66  Med: 16.64 Max: 674.95
Current: 10.77
9.66
674.95
PB Ratio 2.79
DVA's PB Ratio is ranked lower than
60% of the 225 Companies
in the Global Medical Care industry.

( Industry Median: 2.28 vs. DVA: 2.79 )
Ranked among companies with meaningful PB Ratio only.
DVA' s PB Ratio Range Over the Past 10 Years
Min: 2.25  Med: 3.22 Max: 6.46
Current: 2.79
2.25
6.46
PS Ratio 0.93
DVA's PS Ratio is ranked higher than
66% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.49 vs. DVA: 0.93 )
Ranked among companies with meaningful PS Ratio only.
DVA' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.16 Max: 1.77
Current: 0.93
0.77
1.77
Price-to-Free-Cash-Flow 12.17
DVA's Price-to-Free-Cash-Flow is ranked higher than
79% of the 114 Companies
in the Global Medical Care industry.

( Industry Median: 23.68 vs. DVA: 12.17 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.52  Med: 15.98 Max: 42.52
Current: 12.17
7.52
42.52
Price-to-Operating-Cash-Flow 7.02
DVA's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 13.47 vs. DVA: 7.02 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.22  Med: 9.17 Max: 17.87
Current: 7.02
5.22
17.87
EV-to-EBIT 11.06
DVA's EV-to-EBIT is ranked higher than
86% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 19.61 vs. DVA: 11.06 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.1 Max: 20.4
Current: 11.06
8.5
20.4
EV-to-EBITDA 8.02
DVA's EV-to-EBITDA is ranked higher than
85% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 14.29 vs. DVA: 8.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.5 Max: 15.4
Current: 8.02
6.8
15.4
PEG Ratio 1.86
DVA's PEG Ratio is ranked higher than
70% of the 89 Companies
in the Global Medical Care industry.

( Industry Median: 3.12 vs. DVA: 1.86 )
Ranked among companies with meaningful PEG Ratio only.
DVA' s PEG Ratio Range Over the Past 10 Years
Min: 0.41  Med: 1.47 Max: 5.58
Current: 1.86
0.41
5.58
Shiller PE Ratio 25.62
DVA's Shiller PE Ratio is ranked higher than
58% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 28.74 vs. DVA: 25.62 )
Ranked among companies with meaningful Shiller PE Ratio only.
DVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.65  Med: 29.36 Max: 50.42
Current: 25.62
19.65
50.42
Current Ratio 1.48
DVA's Current Ratio is ranked higher than
59% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. DVA: 1.48 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.78 Max: 3.17
Current: 1.48
0.39
3.17
Quick Ratio 1.41
DVA's Quick Ratio is ranked higher than
61% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.16 vs. DVA: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.71 Max: 3.04
Current: 1.41
0.37
3.04
Days Inventory 6.45
DVA's Days Inventory is ranked higher than
77% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 18.84 vs. DVA: 6.45 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.61
Current: 6.45
3.72
8.61
Days Sales Outstanding 47.46
DVA's Days Sales Outstanding is ranked lower than
55% of the 174 Companies
in the Global Medical Care industry.

( Industry Median: 44.22 vs. DVA: 47.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 62.54 Max: 69.35
Current: 47.46
43.53
69.35
Days Payable 17.91
DVA's Days Payable is ranked lower than
79% of the 140 Companies
in the Global Medical Care industry.

( Industry Median: 39.67 vs. DVA: 17.91 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 19.24 Max: 27.07
Current: 17.91
14.92
27.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 126 Companies
in the Global Medical Care industry.

( Industry Median: -2.40 vs. DVA: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: -0.6 Max: 9.3
Current: 3
-22.6
9.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.81
DVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 99 Companies
in the Global Medical Care industry.

( Industry Median: 1.79 vs. DVA: 0.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.12 Max: 2.55
Current: 0.81
0.78
2.55
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.29
DVA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
72% of the 32 Companies
in the Global Medical Care industry.

( Industry Median: 1.77 vs. DVA: 1.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.81
DVA's Price-to-Median-PS-Value is ranked higher than
77% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 1.05 vs. DVA: 0.81 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1 Max: 1.83
Current: 0.81
0.34
1.83
Price-to-Peter-Lynch-Fair-Value 2.22
DVA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
60% of the 52 Companies
in the Global Medical Care industry.

( Industry Median: 1.75 vs. DVA: 2.22 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DVA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.31 Max: 8.16
Current: 2.22
0.56
8.16
Earnings Yield (Greenblatt) % 9.04
DVA's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.94 vs. DVA: 9.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 8.3 Max: 11.8
Current: 9.04
4.9
11.8
Forward Rate of Return (Yacktman) % 13.15
DVA's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 118 Companies
in the Global Medical Care industry.

( Industry Median: 10.02 vs. DVA: 13.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.3  Med: 20.3 Max: 35.1
Current: 13.15
12.3
35.1

More Statistics

Revenue (TTM) (Mil) $14,745
EPS (TTM) $ 4.30
Beta1.04
Short Percentage of Float2.47%
52-Week Range $54.50 - 78.77
Shares Outstanding (Mil)194.60

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 15,279 16,231
EPS ($) 3.56 3.91
EPS without NRI ($) 3.56 3.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.34%
Dividends per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Stocks Buffett Hinted Are Undervalued Based on Buybacks Mar 08 2017 
Another Attempt to Trumpet a Mistake Dec 19 2016 
Are Any of Buffett's Holdings Cheap Enough to Buy? Nov 09 2016 
3 Warren Buffett Stocks Fall to 52-Week Lows Oct 28 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Arnold Van Den Berg's Largest Buys in 1st Quarter Apr 21 2016 
Weekly CEO Sells Highlights Apr 18 2016 
7 High Quality Guru Stocks Apr 11 2016 
Steve Mandel Sells Health Care Stakes Mar 11 2016 
Undervalued, Predictable Companies Include Monsanto and Western Union Mar 10 2016 

More From Other Websites
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against DaVita Inc. and... Mar 24 2017
Deadline Reminder for DaVita Inc. Shareholders – DVA Mar 24 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against DaVita... Mar 24 2017
IMPORTANT INVESTOR ALERT: JFJN LAW Announces Securities Class Action Lawsuit Against DaVita Inc. Mar 23 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against DaVita Inc. and... Mar 22 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of DaVita Inc. of a Class Action Lawsuit... Mar 22 2017
DaVita Shares Online Kidney Diet Resources for National Nutrition Month Mar 22 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against DaVita Inc.... Mar 21 2017
Why Is DaVita (DVA) Up 4.8% Since the Last Earnings Report? Mar 21 2017
DaVita Teammate Awarded Medal of Excellence from American Association of Kidney Patients Mar 21 2017
DaVita's Chief Medical Officer Honored by Renal Physicians Association Mar 20 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 20 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against DaVita Inc. and... Mar 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in DaVita... Mar 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of DaVita Inc. of a Class Action... Mar 17 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against DaVita Inc. and... Mar 17 2017
IMPORTANT INVESTOR ALERT: JFJN LAW Announces Securities Class Action Lawsuit Against DaVita Inc. Mar 16 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against DaVita Inc. and... Mar 15 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 15 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against DaVita Inc.... Mar 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)